Skip to main content

Articles

Lymphoma
Immunotherapy with PD-1 Inhibitors the Newest Break­­through in Hodgkin Lymphoma
Read More
Multiple Myeloma, Oncology
Monoclonal Antibodies Poised to Be “Blockbusters” in Myeloma
Read More
FDA Approvals
Recent FDA Approvals
Read More
Orphan Drug Expenditures in the United States Expected to Stabilize
Read More
Economic Value of Survival Gains for MDS Could Exceed $100 Billion
Read More
Once Off Patent, Imatinib Will Be the Most Cost-Effective Treatment for Newly Diagnosed CML
Read More
High Cancer Drug Prices Hurt Patients
Read More
Stem-Cell Mobilization More Cost-Effective with Plerixafor
Read More
Financial Toxicity Impacts Treatment Adherence
Read More
American-Style Capitalism Drives Drug Development: Cancer Therapies Targeting Small Subpopulations Dictate Prices
Read More
Page 135 of 245
Results 1341 - 1350 of 2441